Discovery of a 1 H-Pyrazol-3-Amine Derivative as a Novel, Selective, and Orally Available RIPK1 Inhibitor for the Treatment of Inflammatory Disease
{{output}}
Receptor-interacting protein kinase 1 (RIPK1) undergoes aberrant activation during the process of cell necroptosis, thereby facilitating and intensifying the inflammatory response. The inhibition of RIPK1 kinase activity is regarded as a promising therapeutic ... ...
